Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New Study
December 04, 2024 16:15 ET
|
OncoCyte Corporation
Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New Study
VivaVision Announces Positive Topline Results from Phase 2 Trial of VVN461 for Post-Operative Inflammation Following Cataract Surgery
December 04, 2024 11:07 ET
|
VivaVision Biotech, Ltd.
VVN461, a non-steroidal dual JAK1/TYK2 immunomodulator, achieves primary endpoint, demonstrating statistical and clinical efficacy compared to vehicle in treating post-operative inflammation following...
Former Merck USA President Joins Klotho Neurosciences’ Board of Directors
December 03, 2024 11:00 ET
|
Klotho Neurosciences, Inc.
Former Merck USA President Joins Klotho Neurosciences’ Board of Directors
Lipella Pharmaceuticals Announces Publication in CUREUS on Non-Steroid Treatment of Oral Lichen Planus
December 03, 2024 08:30 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces Publication in CUREUS on Non-Steroid Treatment of Oral Lichen Planus
Halberd Update on WatchDawg® PTSD Treatment
December 02, 2024 08:00 ET
|
Halberd Corp.
Halberd Update on WatchDawg® PTSD Treatment
FSR Doubles Investment in Cardiac Sarcoidosis Research with $200,000 in Grants to Advance Diagnostic and Treatment Breakthroughs
November 27, 2024 13:51 ET
|
Foundation for Sarcoidosis Research
FSR Doubles Investment in Cardiac Sarcoidosis Research with $200,000 in Grants to Advance Diagnostic and Treatment Breakthroughs
Monoclonal Antibody Collaboration and Licensing Analysis Report 2024 with Directory of 639 Deals Signed Since 2019 by Company A-Z, Deal Type and Therapeutic Target
November 26, 2024 06:29 ET
|
Research and Markets
Dublin, Nov. 26, 2024 (GLOBE NEWSWIRE) -- The "Monoclonal Antibody Collaboration and Licensing Deals 2019-2024" report has been added to ResearchAndMarkets.com's offering. Fully revised and...
Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group
November 21, 2024 05:30 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group
Global Down Syndrome Foundation Raises $2.5 Million at Star-Studded Be Beautiful Be Yourself Fashion Show
November 19, 2024 14:27 ET
|
Global Down Syndrome Foundation
Denver, Nov. 19, 2024 (GLOBE NEWSWIRE) -- On Saturday, November 16, Global Down Syndrome Foundation (GLOBAL) raised $2.5 million at their Be Beautiful Be Yourself Fashion Show, held at the Sheraton...
Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index
November 13, 2024 08:00 ET
|
PRISM MarketView
Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index